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INTRODUCTION
The pathogenesis of human osteoarthritis was, for most of the 20th Century, characterized merely as a 'wear-and-tear' mechanically driven focal musculoskeletal disorder associated with the ageing process [1] for which no medical intervention in addition to joint replacement surgery would 'cure'. It was only a little more than 10 years ago when Pelletier et al. [2] 'reconceptualized' human osteoarthritis as an inflammatory disease of diarthrodial synovial joints for which the inflammation was characterized as 'nonclassical'. Thus, Pelletier et al. [2] , contended that 'nonclassical' inflammation contributed to osteoarthritis synovitis [3] [4] [5] [6] and its pathology, but more importantly inflammation was viewed as the key component in promoting the progression of osteoarthritis cartilage and bone destruction. In fact, Berenbaum [7 More recently, Cicuttini and Wluka [8] proposed that osteoarthritis also be reclassified as a systemic disease rather than a focal disease of the joints. Thus, metabolic-triggered inflammation involving cytokines, adipokines, abnormal metabolites, acute phase reactants, vitamin D deficiency and dysregulated microRNA metabolism all appear to play major roles in osteoarthritis pathophysiology [9 & ]. As we enter the middle of the second decade of the 21st Century, this novel and seminal contrapoint to reclassify osteoarthritis as an inflammatory, systemic disease with abnormal metabolic overtones has been confirmed through many systematic analyses of sera, synovial tissue, synovial fluid, articular cartilage and subchondral bone. Even more than inflammation simply contributing to osteoarthritis, osteoarthritis also appears to involve altered innate and adaptive immunity, which was totally unforeseen until activated T cells were immunolocalized to the synovial tissue of human osteoarthritis joint specimens [10] . In fact, immunemediated inflammation is now considered to be a common finding in osteoarthritis synovial tissue in which immune cell infiltration and cytokine secretion are prominent findings [11] .
Recently, Haseeb and Haqqi [12 && ] proposed a model of osteoarthritis pathogenesis in which multiple aberrations in genetic, homeostatic and/ or mechanical factors described by earlier investigators were incorporated. These abnormalities could include genetic mutations, a skewed balance between anabolic and catabolic cytokines and growth factors as well as evidence for subtle anatomic joint dysplasias contributing to the mechanical abnormalities associated with osteoarthritis. Taken together, these factors would then cause cartilage injury and as a result destroy the integrity of articular cartilage that would potentially expose sequestered cartilage-specific autoantigens to the immune system. Thus, newly produced cartilage autoantigens would then have the capacity to promote immune activation resulting in the migration, adhesion and retention of T cells, B cells and macrophages in joint synovial tissue. In this fashion, cytokines and chemokines would be secreted from activated immune cells, which, in all likelihood, also involve activated complement components as well.
Now we know that in addition to T cells, B cells and macrophages, the degradation of the articular cartilage extracellular matrix proteins in osteoarthritis is brought about by the concerted activity of several matrix metalloproteinases (MMPs), but most prominently, MMP-1 (collagenase-1), MMP-3 (stromelysin-1), MMP-2 (72 kDa gelatinase), MMP-9 (92 kDa gelatinase) and MMP-13 (collagenase-3) [13, 14] as well as another class of enzymes, a disintegrin and metalloproteinase and a disintegrin and metalloproteinase with thrombospondin motif (ADAMTS) [15] of which ADAMTS-4 and ADAMTS-5 appear to be the most critical of the ADAMTS family for initiating the degradation of the large aggregating proteoglycan, aggrecan, in early osteoarthritis [16,17 & ]. Importantly, results from many experimental and clinically based studies [18,19 & ] demonstrated that the proinflammatory cytokines, which were shown to stimulate MMP and ADAMTS gene transcription in normal and osteoarthritis human chondrocyte cultures, were also found at significantly elevated levels in the synovial fluid of patients with osteoarthritis compared with synovial fluids of nonarthritic patients. Thus, these studies also provided compelling evidence that the proinflammatory and anti-inflammatory cytokines, tumor necrosis factora (TNF-a), interleukin-1, interleukin-4, interleukin-6, interleukin-15, interleukin-10, interleukin-13, interleukin-15, interleukin-17, interleukin-18, interleukin-21, as well as chemokines, such as monocyte chemotactic protein-1 (MCP-1), fractalkine and interleukin-8; transcription factors, such as nuclear factor-kappa B (NF-kB) and nuclear factor of activated T cells-1 (NFAT1); members of the bone morphogenetic protein family including the BMP, WNT, GREM1, FRZB and DKK1 genes; growth factors, such as transforming growth factor-b, vascular endothelial growth factor and epidermal growth factor [20, 21] ; leukemia inhibitory factor [22, 23] ;
KEY POINTS
Osteoarthritis is reclassified as a systemic rather than a focal musculoskeletal disorder of synovial joints.
Immune-mediated inflammation is now considered a common finding in osteoarthritis synovial tissue in which immune cell infiltration and cytokine secretion are prominent findings.
In addition to the changes in synovial joints orchestrated by T-cell, B-cell and macrophage infiltration of synovial tissue in osteoarthritis, the degradation of articular cartilage extracellular matrix proteins is caused by the concerted activities of MMPs, a disintegrin and metalloproteinase and ADAMTS.
The repertoire of serum and synovial fluid cytokines reflects their role in the inflammatory response in osteoarthritis patients. Elevated levels of these cytokines are associated with the severity of joint cartilage and subchondral bone damage.
Adipokines are a class of proinflammatory cytokines that also mediate cartilage degradation in osteoarthritis.
hormonally stimulated pain pathways and osteoarthritis susceptibility genes, such as GDF5, all appear to be vital components germane to the osteoarthritis process [24-27,28 & ,29,30 && ,31-33,34 & , [35] [36] [37] [38] . Thus, it is likely that further understanding of how a balance between the proinflammatory and anti-inflammatory cytokine repertoire is maintained will not only reveal the complexity inherent in regulating the destruction of synovial joints in osteoarthritis, but will also be instructive for designing interventional strategies that would have been completely ignored 20 or more years ago. These interventional strategies should now include ways to therapeutically limit synovial tissue inflammation and therefore the joint destruction of osteoarthritis while also potentially stimulating articular cartilage repair.
Cytokine repertoire in synovial fluid and serum reflects their presumed role in osteoarthritis
The cytokine repertoire in serum and synovial fluid from osteoarthritis patients has been employed to determine the extent to which they reflect their role in osteoarthritis [39] . In that regard, the results from a few studies indicated that increased levels of serum interleukin-6 and C-reactive protein (CRP) were consistently higher in individuals diagnosed with radiographic knee osteoarthritis than in a control group [40] . In addition, Moktar et al. [41] found that 57.1% of the cartilages obtained from osteoarthritis patients who underwent total knee replacement contained elevated levels of interleukin-6 compared with normal cartilage. Furthermore, serum levels of interleukin-6 and TNF-a were associated with cartilage loss (measured by joint space narrowing) in older adults with radiographic evidence of osteoarthritis [42] . However, although baseline serum levels of interleukin-6 predicted loss of medial and lateral tibial plateau cartilage volume, this finding was independent of TNF-a. Most importantly, the TNF-a concentration in knee synovial tissue from osteoarthritis patients did not correlate with Kellgren-Lawrence (K-L) grading scores, whereas interleukin-6 had a significantly negative relationship with K-L scores [43] .
Although differences were detected in interleukin-6 and TNF-a using the Western Ontario and McMaster Universities Arthritis Index, an instrument to measure pain, stiffness and physical function in osteoarthritis, this finding suggested that interleukin-6 and TNF-a played a role in synovial inflammation in osteoarthritis but in opposite directions; thus, increased levels of TNF-a levels were associated with pain, whereas increased interleukin-6 levels were associated with joint function. Of note, Abe et al. [44] concluded from their recently published study that elevated levels of interleukin-6 and TNF-a were highly predictive of the rate of ongoing joint destruction in osteoarthritis.
With respect to other cytokines involved in the osteoarthritis process, Barker et al. [45] showed that evidence of early knee osteoarthritis as measured by radiography, pain and muscle weakness parameters was associated with increased serum levels of TNF-a as expected, but also these patients had increased levels of interleukin-5, interleukin-6, interleukin-12 and interleukin-13 compared with patients with late osteoarthritis. This was also the case for serum and synovial fluid levels of interleukin-17, which was higher in osteoarthritis patients compared with controls in which synovial fluid interleukin-17 was increased in association with the higher K-L grade and the Lequesne index [46 & ], the latter a scoring system for determining the severity of hip osteoarthritis, which has also been employed to assess the effectiveness of therapies for hip osteoarthritis.
Studies which measured the concentration of interleukin-2, interleukin-5, MCP-1 and macrophage inhibitory protein-1 (MIF-1) in osteoarthritis synovial fluid also showed a marked elevation in these parameters compared with synovial fluid from those patients with little or no arthritis, indicative that interleukin-5 and these other cytokines were likely to play a role in osteoarthritis progression [47] . Moreover, elevated levels of MIF-1 in the serum and synovial of osteoarthritis patients with a K-L cartilage grade of 4 showed that MIF-1 levels were associated with the radiographic severity of osteoarthritis [48] .
Interleukin-1b levels are generally elevated in osteoarthritis synovial fluid. Thus, interleukin-1b was considered to be an important component in osteoarthritis pathogenesis and progression [49] . However, the median synovial fluid concentration of interleukin-1a was shown to be increased when patients with 'mild' osteoarthritis were compared with patients with 'moderate' osteoarthritis, which was not the case with interleukin-1b [50] . However, this finding was reexamined by Tsuchida et al. who found that interleukin-1a and interleukin-1b was markedly higher in osteoarthritis cartilage than in osteoarthritis synovial fluid. In addition, interleukin-6, interleukin-13, interferon-a and oncostatin M (OSM) levels in synovial fluid were higher in patients with cartilage disorder compared with nonpathologic synovial fluids. Thus, the overall cytokine repertoire, including interleukin-1b, of osteoarthritis synovial fluid was primarily dependent on the extent of osteoarthritis disease. Importantly, human chondrocyte cultures derived from these pathologic cartilage samples produced a cytokine repertoire reminiscent of the very same cytokines that are elevated in osteoarthritis synovial fluid.
Adipokines are a family of cytokines with a prominent role in osteoarthritis
Adiponectin, a member of the adipokine family was shown to be a mediator of cartilage extracellular matrix protein degradation through its capacity to increase MMP and inducible nitric oxide synthase-II (iNOS-II) gene expression [52, 53] . Induction of MMP and iNOS-II by adiponectin also required activation of human chondrocyte adenosine monophosphate protein kinase and c-Jun-amino-terminal kinase signaling [53] .
Other analyses of adipokine-induced changes associated with osteoarthritis showed that although adipokine levels were higher in sera from osteoarthritis patients compared with sera from nonosteoarthritis patients, there was no association between adipokine levels in osteoarthritis sera and damage to articular cartilage determined by proteoglycan content and histochemical analysis of cartilage specimens [54] . However, a weak, but positive, correlation between adiponectin (as well as interleukin-1b) was found with respect to the inflammatory state of osteoarthritis synovial tissue. Resistin, another member of the adipokine family, was found at elevated levels in osteoarthritis synovial fluid [55 && ]. Furthermore, resistin levels in osteoarthritis synovial fluid correlated with the level of interleukin-6, MMP-1 and MMP-3. Furthermore, resistin levels in osteoarthritis plasma were positively correlated with resistin levels in osteoarthritis synovial fluid. Nefastin-1, another member of the adipokine family, was elevated in the sera of patients with osteoarthritis of the knee, but nefastin-1 levels in osteoarthritis sera exceeded that of osteoarthritis synovial fluid [56] . Of note, serum nefastin-1 levels were positively correlated with high-sensitivity CRP and interleukin-18, suggesting a relationship between nefastin-1, inflammation and osteoarthritis disease. Visfatin/nicotinamide phosphoribosyl transferase (Nampt), another member of the adipokine family, was found to be released into the culture medium by osteoarthritis synovial tissue ex vivo [57 & ]. Moreover, visfatin significantly increased interleukin-6, keratinocyte chemoattraction factor and MCP-1 levels by cultured chondrocytes and osteoblasts. All three of these molecules were decreased by adding APO866 (Daporinad), an inhibitor of Nampt enzyme activity to the culture medium. Thus, Nampt activity appeared to be involved in chondrocyte and osteoblast activation, and, as such, Nampt may be another suitable target for osteoarthritis by determining the extent to which inhibition of Nampt enzyme activity alters osteoarthritis progression. Additional weight was added to this possibility as Yang et al. [58] had previously shown that Nampt protein increased MMP-1, MMP-12 and MMP-13 as well as hypoxiainducible factor-1a mRNA in articular chondrocytes and in osteoarthritis cartilage explants in vitro, suggesting that Nampt was likely a strong catabolic factor in determining the extent of osteoarthritis cartilage damage.
CONCLUSION
The role of cytokines as orchestrators of osteoarthritis pathogenesis and progression has been a focus of attention by basic and clinical investigators for many years. However, despite the fact that a proinflammatory cytokine, such as interleukin-1b, was implicated in osteoarthritis disease, osteoarthritis clinical trials employing several anti-interleukin-1 strategies have generally been disappointing as they lacked significant clinical efficacy [49, [59] [60] [61] .
Unfortunately, at present, there are no novel US Federal Drug Administration approved anticytokine therapies for osteoarthritis. However, recent developments have implicated other cytokines in addition to interleukin-1 in the osteoarthritis process, including interleukin-6. In addition, showing that interleukin-17, interleukin-18 [62] , interleukin-15 and TNF-a correlate with osteoarthritis disease has provided the impetus for focusing some attention on these cytokines as potential targets for osteoarthritis therapeutic intervention. Moreover, identifying cytokines belonging to the adipokine family of proteins such as adiponectin [52, 53] and OSM [63] as mediators of osteoarthritis cartilage and subchondral bone abnormalities has also been advanced due, in part, to the role that adipokines play in promoting the expression of MMP genes by chondrocytes. These findings have implicated adipokines as playing an important role in the degradation of articular cartilage extracellular matrix proteins. This advance in our knowledge base is particularly important as MMP inhibitor strategies exploiting paradigms of medicinal chemistry [64] , which were essentially designed to directly inhibit MMP activity by articular chondrocytes in osteoarthritis cartilage, have been unsuccessful when these MMP inhibitors were employed in osteoarthritis clinical trials [65] . Because of these failures, novel approaches may have to be employed to take advantage of those signal transduction pathways that are likely to govern gene expression in osteoarthritis and, therefore specifically to dampen MMP gene expression [14] . However, despite failed opportunities, new tactics to develop 'selective' proteinase inhibitors for ameliorating osteoarthritis progression do not seem beyond the realm of possibility [66] . Therefore, the next period of basic and clinical osteoarthritis research will be forced to take into account the mounting evidence, which points to a targeted genomic approach to limit proinflammatory cytokine-induced changes in synovial joint immune-mediated inflammation. This could also include the 'fine-tuning' of the chondrocyte reactive oxygen species responses, which have been shown to alter chondrocyte mitochondrial function [67] .
Finally, the future of osteoarthritis therapeutic drug development will likely require the use of biologic approaches designed to alter the pathologic responses and activities of chondrocytes, synoviocytes and macrophages. Thus, drug development strategies such as those employed to successfully treat rheumatoid arthritis (RA) may also have to be aligned with those strategies that analyze the effects of these biologic drugs as inhibitors of osteoarthritis chondrocyte, macrophage and synoviocyte MMPs [68] [69] [70] [71] [72] [73] 74 & ,75]. These agents will also have to be assessed for their ability to ameliorate osteoarthritis in preclinical animal models and then going forward tested to determine their clinical efficacy in osteoarthritis clinical trials as was shown to be the case for biologic drugs in use for the treatment of RA.
Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis Cartilage 2013; 21:16-21. At one time osteoarthritis was considered to be driven only by the altered structure of articular cartilage. Now osteoarthritis must be reevaluated and characterized as a complex disease orchestrated by inflammatory mediators produced by cartilage, bone and synovium. 
